Humanwell Pharmaceutical ranks 13th on the 2021 China Drug Research and Development Comprehensive St

      Humanwell Pharmaceutical ranks 13th on the 2021 China Drug Research and Development Comprehensive Strength Ranking Top 100

        The 2021 China Pharmaceutical R&D Strength Ranking Series of Rankings is a comprehensive statistical analysis of multiple R&D related data from various enterprises, including the acceptance and approval of drugs in 2020, R&D investment by pharmaceutical companies, completion of clinical trials, and patent layout. Excluding the influence of market and sales layout, it is one of the most authoritative and influential rankings in the pharmaceutical industry, Representing the highest level of comprehensive research and development strength of Chinese pharmaceutical enterprises.

        Through comparative analysis of the list, it was found that the application and registration of new drugs reached a new high after the drug approval reform, with half of the top 100 research and development enterprises accounting for the majority. As the core force for the transformation and upgrading of China's pharmaceutical industry and the creation of industrial competitiveness, Renfu Pharmaceutical Group is firmly committed to the path of innovation driven development. In 2020, the group successively obtained drug registration approvals for products such as Class I chemical drug Remazolam Benzenesulfonate for Injection, Class III chemical drug Alfentanil Hydrochloride Injection, Class IV chemical drug Tadalafil Tablets, Sorinaxin Succinate Tablets, and Alishentan Tablets; The Chinese and American dual reported varieties of metformin hydrochloride sustained-release tablets and bupropion hydrochloride sustained-release tablets have been approved for marketing in China; A total of 30 standard products of 17 varieties, including Fentanyl Citrate Injection, sufentanil Citrate Injection, remifentanil Hydrochloride for Injection, Mifepristone Tablets and other major products, passed the consistency evalsuation of generic drugs (including deemed to pass).

       In 2021, the group continued to deepen research and development innovation around its core product line. The chemical class 1 new drug for inducing general anesthesia in adults, disodium phosphopropofol for injection, has been approved for production. As of now, the group has two exclusive seats among the three approved chemical class 1 new drugs in Hubei Province, marking a significant leap in the innovation strength of the group from being international and leading. In addition, three types of chemical drugs, midazolam oral solution, hydromorphones hydrochloride injection (new specifications), potassium chloride sustained-release tablets, and bupropion hydrochloride sustained-release tablets (II), have been approved successively; Varieties such as omeprazole sodium for injection and metoprolol tartrate injection have successively passed consistency evalsuations (including deemed passing).

In the future, Renfu Pharmaceutical Group will firmly adhere to the "differentiation+innovation" research and development strategy, comprehensively improve research and development efficiency, focus on unmet clinical needs, develop new drugs and methods with clinical value and advantages that can effectively solve patient pain, and strive to improve the quality of life of the people.